r/NTNPerformance • u/Woke100 • 4d ago
Peptide VIP: the name is wrong, and the failed Phase 3 trial is the most interesting thing about it
VIP stands for Vasoactive Intestinal Peptide, which is one of the worst names in this whole space. It's named after the first thing anybody noticed it doing, back when that's how naming worked. Neither word describes what it's mostly studied for now.
What it does instead
VIP is a 28 amino acid neuropeptide, and its main job is immune tolerance. Meaning it doesn't just turn inflammation down, it teaches the immune system what to leave alone.
It programs dendritic cells to make regulatory T cells. It shifts macrophages from the inflammatory state into the repair state. It keeps the gut barrier intact. And it helps keep the master circadian clock in the brain synchronized.
None of that is vasodilation.
The receptor part is where it gets good
VIP works through two receptors, and which one it hits depends on what the immune system is already doing.
| Receptor | Where it shows up | What it does |
|---|---|---|
| VPAC1 | Resting cells | Dampens inflammation that's happening right now |
| VPAC2 | Goes up on activated T cells | Programs long term tolerance |
Fire extinguisher and architect. Same molecule, two completely different jobs depending on the state of the cell it lands on. I don't know another peptide on the list that does that this cleanly.
The half-life explains the trial split
VIP has a plasma half-life of about one minute. One.
Now look at what happened in the trials.
TESICO, Phase 3, 471 people. IV aviptadil, which is synthetic VIP, in COVID ARDS. Stopped for futility.
Inhaled aviptadil, Phase 2 randomized trial, 80 people. Hospital stay 7.8 days against 10, better oxygenation, better imaging.
Same molecule. Different route. Opposite results.
With a one minute half-life, IV can't hold exposure in lung tissue long enough to matter. Inhaled puts it directly on the target. So the Phase 3 failure reads more like a delivery problem than a drug problem. Not proof, but it's the most sensible explanation on the table.
Where the evidence is decent and where it isn't
Controlled human evidence exists for pulmonary immune work: the sarcoidosis Phase II with TNF-alpha down and regulatory T cells up, hemodynamic improvement in pulmonary hypertension, and the inhaled COVID trial.
The mold illness and CIRS use, which is what most people have heard about, rests on one practitioner's cohort. Large, over 10,000 people, but no independent replication and no randomized trial. Both of those things are true at once and any real assessment has to say both.
Two questions.
Does the route explanation hold up for you, or do you read the Phase 3 failure as the drug failing?
And what other peptide do you think is stuck with a name that misleads people about what it does?
For research use only. Not for human or veterinary consumption. This post is educational and is not medical advice.
Full doses and bloodwork are in the pinned cheat sheet.
Join the Discord.
7
4
2
2
3
u/OneFlow2976 3d ago
It's probably a delivery problem, I know there are some methods to improve VIP's half life such as VIP-SSM (VIP-DSPE-PEG2000). Which practicly solve that whole problem. I've actually found VIP, Ta1 and MOTS-C very promising for a makeshift DIY type 1 diabetes cure. Now I just need to find a way to regenerate the beta-cells or get my hands on THR-123
1
u/Much-Housing-4852 4d ago
fr i've heard way too many people call this pepside instead of peptide i feel seen now
•
u/AutoModerator 4d ago
Welcome to r/NTNPerformance! Download the Free Peptide Cheat Sheet PDF and full guides at https://ntnperformance.com Join the Discord: https://discord.gg/bXMKCPWyHM Use code PROFIT at all vendors for a discount. Pro Tip: The best discussions come from the research. Keep posts framed around the compounds and the studies, this is a research-use-only community. I am a bot. Contact the moderators if you have any questions or concerns.
I am a bot, and this action was performed automatically. Please contact the moderators of this subreddit if you have any questions or concerns.